Table 4.
TPE vs. IVIG response rates and sizes in acute MG data.
| Reference | Ramos-Fransi et al. (43) | Guptill et al. (44) | Barth et al. (5) | Murthy et al. (47) | Qureshi et al. (42) | Gajdos et al. (41) |
|---|---|---|---|---|---|---|
| Treatment context | Retrospective | Retrospective | Prospective | Retrospective | Retrospective | Prospective |
| Comparison | Acute | Acute | Acute | Acute | Acute | Acute |
| Study type | Severe | Mild to severe | Moderate | Severe | Severe | Moderate to severe |
| Severity | AChR+ (90%) | MuSK+ (100%) | AChR+ (75%) | Not specified | Not specified | AChR+ (70%) |
| Common serotype | TPE/IVIG | TPE/IVIG | TPE/IVIG | TPE/IVIG | TPE/IVIG | TPE/IVIG |
| # Patients | 6/11 | 73/31 | 43/41 | 15/8 | 28/26 | 41/46 |
| Timing (response rate) | 30 days | Not specified | 14 days | At discharge | 28 days | 15 days |
| Response rate | MGFA-PIS: 50/36% | MGFA-PIS: 93/61%∧ | ΔQMGS ≥ 3.5: 58/51% MGFA-PIS: 65/ 69% | Clinician definition of complete resolution: 93/88% | Clinician definition of complete resolution: 71/62% | ΔMMS ≥ 20: 63/48% |
| Timing (response size) | - | - | 14 days | - | 7 days | 15 days |
| Response size | - | - | ΔQMGS:4.7 ± 4.9/3.2 ± 4.1* | - | ΔMSS: 4.2/2.8 | ΔMMS: 16.6 ± 5.0/15.6 ± 4.7 (95% Cl)* |
No significant difference observed between treatments (p ≥ 0.05) unless noted.
∧
p < 0.05 as reported by original authors or calculated using Fisher exact test.
*
Combined data from two separate IVIG groups: 3-day IVIG treatment 18.9 (95% Cl: 13.1, 24.7) and 5-day IVIG treatment 12.4 (95% Cl: 5.0, 19.8).